Influence of chronic inflammation and autoimmunity on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients

Inflammation Research

Volumn 60, Issue 10, 2011, Pages 973-980

  Plazak, Wojciech ^a   Pasowicz, Mieczyslaw ^a   Kostkiewicz, Magdalena ^a   Podolec, Jakub ^a   Tomkiewicz Pajak, Lidia ^a   Musial, Jacek ^b   Podolec, Piotr ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Atherosclerosis; Autoimmune diseases; Coronary calcification; MDCT; Perfusion scintigraphy; SPECT; Systemic lupus erythematosus

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C3C; COMPLEMENT COMPONENT C4; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS ANTICOAGULANT; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PHOSPHOLIPID ANTIBODY;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CIGARETTE SMOKING; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY DISEASE; CORONARY CALCIUM SCORING; DIABETES MELLITUS; EXERCISE; FEMALE; HEART MUSCLE PERFUSION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; OBESITY; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; AUTOIMMUNITY; CALCINOSIS; COMPLEMENT C3C; COMPLEMENT C4; CORONARY VESSELS; FEMALE; HUMANS; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MYOCARDIUM; PERFUSION; RISK FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80955158816     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-011-0358-x     Document Type: Article

References (38)

1. Bruce IN. ''Not only⋯ but also'': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology. 2005;44: 1492-502. (Pubitemid 41742464)
2. Pons-Estel GJ, Gonzales LA, Zhang J, Burgos PI, Reveille JD, Alarcon GS. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multicenter US cohort. Rheumatology. 2009;48:817-22.
3. Wiik AS, Fritzler MJ. Laboratory tests in rheumatic disorders. In: Hochberg M, Silman A, Smolen J, Weinblatt M, Weisman M, editors. Rheumatology. Philadelphia: Mosby Elsevier; 2008. p. 219-32.
4. Del Papa N, Guidali L, Sala A, Buccellati C, Khamashta MA, Ichikawa K, et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal antib2glycoprotein- 1 induced endothelial cell activation. Arthritis Rheum. 1997;40:551-61.
5. Pierangeli SS, Espinola RG, Liu XW, Harris EN. Thrombogenic effect of antiphospholipid antibodies are mediated by intracellular adhesion molecule-1, vascular cell adhesion molecule-1 and P-selectin. Circ Res. 2001;88:245-50. (Pubitemid 32147315)
6. Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effect of anticardiolipin antibodies from patients with antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost. 1995;73: 519-24.
7. Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by anti-phospholipid antibodies. J Clin Invest. 1995;95:309-16.
8. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite anti phospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
9. Swadzba J, de Clerck LS, Stevens WJ, Bridts CH, van Cotton KA, Musial J, et al. Anticardiolipin antibodies, anti-b2-glycoprotein I, antiprothrombin antibodies and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis. J Rheumatol. 1997;24:1710-5. (Pubitemid 27394506)
10. Smolen J, Weisman M. Connective tissue disorders. In: Hochberg M, Silman A, Smolen J, Weinblatt M, Weisman M, editors. Rheumatology. Philadelphia: Mosby Elsevier; 2008. p. 1205-485.
11. Smith EL, Shmerling RH. The American College of Rheumatology criteria for the classification of systemic lupus erythematosus: strengths, weaknesses, and opportunities for improvement. Lupus. 1999;8:586-95. (Pubitemid 29520523)
12. Permarheum SLEDAI Calculator: http://www.permarheum.org/ SLEDAI.html.
13. AgatsonAS, JanowitzWR,Hildner FJ, ZusmerNR, ViamonteMJr, Detrano R. Quantification of coronary artery calciumusing ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827-32. (Pubitemid 20101575)
14. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standarisation committee of the international society on thrombosis and haemostasis. J Thromb Haemost. 2009;7:1737-40.
15. Lin CC, Ding HJ, Chen YW, Wang JH, Ho ST, Kao A. Usefulness of technetium-99 m sestamibi myocardial perfusion SPECT in detection of cardiovascular involvement in patients with systemic lupus erythematosus or systemic sclerosis. Int J Cardiol. 2003;92:157-61. (Pubitemid 37509976)
16. Lin JJ, Hsu HB, Sun SS, Wang JJ, Ho ST, Kao CH. Single photon emission computed tomography of technetium-99 m tetrofosmin myocardial perfusion imaging in patients with systemic lupus erythematosus-a preliminary report. Jpn Heart J. 2003;44: 83-9.
17. Vanzetto G, Ormezzano O, Fagret D, Comet M, Denis B, Machecourt J. Long term additive prognostic value of thalium- 201 myocardial perfusion imaging over clinical and exercise stress test in low to intermediate risk patients: study in 1,137 patients with 6 year follow-up. Circulation. 1999;100:1521-7. (Pubitemid 29461464)
18. Hachamovitch R, Berman DS, Shaw LJ, Kiat H, Cohen I, Cabico JA, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. Circulation. 1998;98:190.
19. Petri M. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): hopkins lupus cohort. Thromb Res. 2004;114:593-5. (Pubitemid 39422596)
20. Yiu KH, Wang S, Mok MY, Ooi GC, Khong PL, Mak KF, et al. Pattern of arterial calcification in patients with systemic lupus erythematosus. J Rheumatol. 2009;36:2212-7.
21. Kao AH, Wasko M, Krishnaswami S, Wagner J, Edmundowicz D, Shaw P, et al. C-reactive protein and coronary artery calcium in asymptomatic women with systemic lupus erythematosus or rheumatoid arthritis. Am J Cardiol. 2008;102:755-60.
22. Raggi P, Gongora M, Gopal A, Callister T, Budoff M, Shaw L. Coronary artery calcium to predict all-cause mortality in elderly men and women. J Am Coll Cardiol. 2008;52:17-23. (Pubitemid 351858598)
23. Chang SM, Nabi F, Xu J, Peterson LE, Achari A, Pratt CM, et al. The coronary artery calcium score and stress myocardial perfusion imaging provide independent and complementary prediction of cardiac risk. J Am Coll Cardiol. 2009;54:1872-82.
24. Polonsky TS, McClelland RL, Jorgensen NW, Bild DE, Burke GL, Guerci AD, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA. 2010;303:1610-6.
25. Uebleis C, Becker A, Griesshammer I, Cumming P, Becker C, Schmidt M, et al. Stable coronary artery disease: prognostic value of myocardial perfusion SPECT in relation to coronary calcium scoring-long-term follow-up. Radiology. 2009;252:682-90.
26. Farzaneh-Far A, Roman MJ, Lockshin MD, Devereux RB, Paget SA, Crow MK, et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum. 2006;54:3918-25. (Pubitemid 44955895)
27. Gabrielli F, Alcini E, Prima MA, Lucifero A, Masala C. Cardiac involvement in connective tissue diseases and primary antiphospholipid syndrome: echocardiographic assessment and correlation with antiphospholipid antibodies. Acta Cardiol. 1996;51:425-39. (Pubitemid 26390612)
28. Cefle A, Inanc M, Sayarlioglu M, Kamali S, Gul A, Ocal L et al. Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol Int. 2011; 31:183-189.
29. Hasegawa EM, Caleiro MT, Fuller R, Carvalho JF. The frequency of anti-beta2-glycoprotein I antibodies is low and these antibodies are associated with pulmonary hypertension in mixed connective tissue disease. Lupus. 2009;18:618-21.
30. Roitt I. Autoimmunity and autoimmune diseases. In: Male D, Brostoff J, Roth DB, Roitt I, editors. Immunology. London: Mosby Elsevier; 2006.
31. Glueck CJ, Lang JE, Tracy T, Sieve-Smith L, Wang P. Evidence that anticardiolipin antibodies are independent risk factors for atherosclerotic vascular disease. Am J Cardiol. 1999;83:1490-4. (Pubitemid 29228349)
32. Le Tonqueze M, Salozhin K, Dueymes M, Piette JC, Kovalev V, Shoenfeld Y, et al. Role of b2-glycoprotein I in the antiphospholipid antibody binding to endothelial cells. Lupus. 1995; 4:179-86.
33. Kabakov AE, Tertov VV, Saenko VA, Poverenny AM, Orekhow AN. The atherogenic effect of lupus sera: systemic lupus erythematosus- derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. Clin Immunol Immunopathol. 1992;62:214-20.
34. Grainer DJ, Bethell HW. High titers of serum antinuclear antibodies, mostly directed against nucleolar antigens, are associated with the presence of coronary atherosclerosis. Ann Rheum Dis. 2002;61:110-4. (Pubitemid 34098424)
35. Fox K, Garcia M, Ardissino D, Buszman P, Camici P, et al. Guidelines on the management of stable angina pectoris. The task force on the management of stable angina pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341-81. (Pubitemid 43998110)
36. Giron-Gonzales JA, Garcia del Rio E, Rodriguez C, Rodriguez- Martorell J, Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2004;31:1560-7. (Pubitemid 39006638)
37. Wahl DG, Bounameaux H, de Moerloose P, Sarasin FP. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med. 2000;160:2042-8. (Pubitemid 30437588)
38. Petri M, Kiani A, Post W, Christopher-Stine L, Madger L. Lupus atherosclerosis prevention study (LAPS). Ann Rheum Dis. 2011;70:760-5.